Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Hae‐Kyung Kim, Geert Jan Biessels, Min Yu, et al.
Neurology (2024) Vol. 103, Iss. 8
Closed Access | Times Cited: 12

Showing 12 citing articles:

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Joyce Yip, Grace Shu Hui Chiang, I Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 364-364
Open Access
Cognitive dysfunction in diabetes – the ‘forgotten’ diabetes complication: a narrative review
Åke Sjöholm, Louise Bennet, Peter M. Nilsson
Scandinavian Journal of Primary Health Care (2025), pp. 1-7
Open Access
Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study
Lin Zhuo, Baixue Zhang, Yueqi Yin, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
C. Duta, Corina Muscurel, Carmen Beatrice Dogaru, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1516-1516
Open Access
Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes & Metabolism (2025), pp. 101623-101623
Closed Access
Parkinson's disease and glucose metabolism impairment
Liangjing Chen, Chunyu Wang, Lixia Qin, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access
Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
Osvaldo P. Almeida
Current Opinion in Psychiatry (2025)
Closed Access
Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes
Virginia Boccardi, Gülistan Bahat, Cafer Balcı, et al.
European Geriatric Medicine (2025)
Open Access
Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Molecules (2024) Vol. 29, Iss. 24, pp. 5936-5936
Open Access | Times Cited: 1
Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3/Nurr1/GSK-3β/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats
Ahmed M. Abdelaziz, Nora O. Abdel Rasheed, Hala F. Zaki, et al.
International Immunopharmacology (2024) Vol. 146, pp. 113839-113839
Closed Access | Times Cited: 1
Latest clinical research
Mark Greener
Independent Nurse (2024) Vol. 2024, Iss. 11, pp. 12-13
Closed Access
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study
Filippos Anagnostakis, Michail Kokkorakis, S. Nagarajan, et al.
(2024)
Closed Access
Page 1

Scroll to top